6:12 PM
 | 
Mar 04, 2013
 |  BC Extra  |  Clinical News

Celgene provides more apremilast psoriasis data

Celgene Corp. (NASDAQ:CELG) said 33.1% of patients receiving twice-daily oral apremilast achieved a PASI 75 response at week 16, the primary endpoint, vs. 5.3% for patients receiving placebo in the Phase III ESTEEM 1 trial to treat moderate to severe plaque psoriasis (p<0.0001). Celgene said that a significantly greater proportion of patients who received apremilast across all patients populations achieved a PASI 75 response...

Read the full 303 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >